Skip to main content
    V

    Vir Biotechnology Inc (VIR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.58
    -0.38 (-3.82%)

    Market Cap: $1.71B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Vir Biotechnology Inc (VIR) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Vir Biotechnology reported revenue of $68.56M for the fiscal year ended Dec 31, 2025, down 7.6% from the year before. That year, net income was -$437.99M with a net margin of -638.9%, operating cash flow was -$391.78M and free cash flow was -$396.61M. The quarter ended Sep 30, 2026 had revenue of -$188.00K and net income of -$96.25M.

    Revenue and Margins

    Over the 8 years to Dec 2025, revenue grew from $2.71M, a compound annual rate of 49.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$68.56M-7.6%100.0%-699.2%-638.9%
    Dec 2024$74.20M-13.9%98.9%-791.3%-703.4%
    Dec 2023$86.18M-94.7%96.8%-794.0%-713.8%
    Dec 2022$1.62B+47.5%90.9%51.6%31.9%
    Dec 2021$1.10B+1334.4%94.0%38.4%48.3%
    Dec 2020$76.37M+843.9%100.0%-388.9%-391.1%
    Dec 2019$8.09M-24.2%100.0%-2199.7%-2159.0%
    Dec 2018$10.67M+293.9%100.0%-1112.6%-1086.3%
    Dec 2017$2.71MN/A100.0%-3009.5%-2579.5%
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$68.56M$74.20M$86.18M$1.62B$1.10B$76.37M$8.09M$10.67M$2.71M
    Cost of revenue$26.00K$845.00K$2.77M$146.32M$65.86M$0$0$0$0
    Gross profit$68.53M$73.36M$83.42M$1.47B$1.03B$76.37M$8.09M$10.67M$2.71M
    Research and development$455.97M$506.50M$579.72M$474.65M$448.01M$302.41M$148.47M$100.23M$62.51M
    Operating income-$479.33M-$587.16M-$684.30M$833.07M$420.75M-$296.98M-$177.98M-$118.69M-$81.50M
    Net income-$437.99M-$521.96M-$615.12M$515.84M$528.58M-$298.67M-$174.68M-$115.88M-$69.85M
    EBITDA-$456.85M-$574.96MN/AN/A$554.93M-$294.46MN/A-$116.48M-$80.98M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue-$188.00K$238.95M$0$64.31M$240.00K$1.21M$3.03M$12.37M$2.38M$3.08M$56.38M$16.79M
    Gross profit-$188.00K$238.95M$0$64.30M$240.00K$1.20M$3.03M$11.69M$2.33M$3.02M$56.32M$15.99M
    Operating income-$104.66M$73.47M-$132.29M-$47.92M-$173.44M-$118.42M-$139.55M-$117.15M-$231.30M-$158.63M-$80.08M-$139.02M
    Net income-$96.25M$80.08M-$125.69M-$42.92M-$163.14M-$110.96M-$120.97M-$104.59M-$213.72M-$138.38M-$65.28M-$115.97M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $8.80M by $223.39M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$1.00B$1.40B$1.92B$2.80B$1.95B$918.76M$512.07M$191.60M$251.57M
    Current assets$514.08M$1.04B$1.59B$2.52B$1.56B$772.37M$403.00M$117.78M$192.35M
    Cash and equivalents$232.19M$222.95M$241.58M$848.63M$347.81M$436.57M$109.33M$47.60M$187.92M
    Total liabilities$237.55M$248.43M$328.82M$724.13M$522.42M$201.91M$88.13M$61.64M$320.48M
    Short-term debt$8.80M$16.06M$0$4.14M$0$10.60M$8.20M$0$0
    Shareholder equity$765.28M$1.15B$1.59B$2.08B$1.43B$716.85M$423.94M-$179.18M-$68.92M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.11B$1.21B$1.03B$1.00B$1.02B$1.19B$1.31B$1.40B$1.50B$1.67B$1.79B$1.92B
    Total liabilities$215.82M$232.31M$212.82M$237.55M$223.35M$245.06M$263.91M$248.43M$257.63M$235.88M$246.61M$328.82M
    Cash and equivalents$218.87M$278.73M$274.16M$234.11M$170.08M$211.10M$273.57M$222.95M$168.35M$296.86M$160.71M$241.58M
    Shareholder equity$896.04M$982.49M$812.76M$765.28M$796.10M$947.47M$1.04B$1.15B$1.24B$1.43B$1.55B$1.59B
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$391.78M-$446.35M-$778.78M$1.66B-$47.59M-$190.94M-$129.63M-$94.10M-$66.38M
    Capital expenditures$4.83M$7.30M$21.57M$68.01M$21.82M$6.55M$8.94M$9.94M$2.74M
    Free cash flow-$396.61M-$453.65M-$800.36M$1.60B-$69.41M-$197.49M-$138.57M-$104.03M-$69.12M
    Investing cash flow$310.37M$499.37M$164.63M-$1.19B-$140.81M-$9.86M-$256.16M-$60.44M-$29.99M
    Financing cash flow$3.79M$4.39M$7.48M$34.76M$100.33M$529.47M$449.24M$24.98M$271.18M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$106.08M$123.33M-$132.39M-$25.88M-$167.57M-$120.22M-$78.12M-$87.64M-$171.48M-$77.85M-$109.39M-$107.93M
    Capital expenditures$34.00K$32.00K$390.00K$348.00K$317.00K$2.54M$1.63M$2.00M$2.77M$666.00K$1.87M$1.53M
    Free cash flow-$106.11M$123.29M-$132.78M-$26.22M-$167.89M-$122.76M-$79.75M-$89.63M-$174.25M-$78.51M-$111.26M-$109.46M
    Last 12 quarters

    Frequently Asked Questions About VIR

    What is Vir Biotechnology's annual revenue?

    Vir Biotechnology reported revenue of $68.56M for the fiscal year ended Dec 31, 2025.

    How fast is Vir Biotechnology's revenue growing?

    Revenue was down 7.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -65.1%.

    Is Vir Biotechnology profitable?

    No. Vir Biotechnology reported net income of -$437.99M for the fiscal year ended Dec 31, 2025, with a net margin of -638.9%.

    How much free cash flow does VIR generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$391.78M minus capital expenditures of $4.83M produced free cash flow of -$396.61M.

    How much debt does Vir Biotechnology have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $8.80M and cash and equivalents of $232.19M.